Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects von SHAW, J. P, SEROOGY, J, KANIGA, K, HIGGINS, D. L, KITT, M, BARRIERE, S

Volltext

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior tr... von Gomez, Henry L, Philco, Manuel, Pimentel, Patricia, Kiyan, Miriam, Monsalvo, Maria Laura, Conlan, Maureen G, Saikali, Khalil G, Chen, Michael M, Seroogy, Joseph J, Wolff, Andrew A, Escandon, Rafael D

Volltext

Nitrous Oxide for the Management of Labor Pain: A Systematic Review von Likis, Frances E., Andrews, Jeffrey C., Collins, Michelle R., Lewis, Rashonda M., Seroogy, Jeffrey J., Starr, Sarah A., Walden, Rachel R., McPheeters, Melissa L.

Volltext

Abuse-resistant opioid prodrugs that demonstrate oral overdose protection von Jenkins, T, Husfeld, C, Cremin, J, Kolesnikov, A, Pelc, L, Seroogy, J, Wray, J

Volltext

Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor von FRETTO, L. J, SNAPE, A. J, TOMLINSON, J. E, SEROOGY, J. J, WOLF, D. L, LAROCHELLE, W. J, GIESE, N. A

Volltext

Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects von SUN, Heather K, DUCHIN, Kenneth, NIGHTINGALE, Charles H, SHAW, Jeng-Pyng, SEROOGY, Julie, NICOLAU, David P

Volltext

Nitrous Oxide for the Management of Labor Pain: A Systematic Review: Erratum

Volltext

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template von Pandey, A., Seroogy, J., Volkots, D., Smyth, M.S., Rose, J., Mehrotra, M.M., Heath, J., Ruhter, G., Schotten, T., Scarborough, R.M.

Volltext

Spirocyclic nonpeptide glycoprotein IIb–IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes von Smyth, M.S, Rose, J, Mehrotra, M.M, Heath, J, Ruhter, G, Schotten, T, Seroogy, J, Volkots, D, Pandey, A, Scarborough, R.M

Volltext

A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein Inhibitor, Dosed Every Two Weeks as First Line Chemotherapy for Advanced Locally Recurrent or Metastatic Breast Cancer von Gomez, H., Philco, M., Pimentel, P., Escandon, R., Saikali, K., Seroogy, J., Wolff, A., Conlan, M.

Volltext

Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family von Pandey, Anjali, Volkots, Deborah L, Seroogy, Joseph M, Rose, Jack W, Yu, Jin-Chen, Lambing, Joseph L, Hutchaleelaha, Athiwat, Hollenbach, Stanley J, Abe, Keith, Giese, Neill A, Scarborough, Robert M

Volltext

A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic... von Gomez, H. L., Philco, M., Castaneda, C., Pimentel, P., Escandon, R., Seroogy, J., Saikali, K., Wolff, A., Conlan, M.

Volltext

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL) von O'Connor, Owen A, Gerecitano, J., Van Deventer, H., Afanasyev, B., Hainsworth, J., Chen, M., Saikali, K., Seroogy, J., Escandon, R., Wolff, A., Conlan, MG

Volltext

A phase I-II trial of Ispinesib , a kinesin spindle protein inhibitor, dosed every two weeks in patients with locally advanced or metastatic breast cancer previously untreated with... von Gomez, H, Castaneda, C, Philco, M, Pimentel, P, Falcon, S, Escandon, R, Saikali, K, Conlan, M, Seroogy, J, Wolff, A

Volltext

A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 dosed q14d without and with prophylactic G-CSF in non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) von Gerecitano, J. F., O'Connor, O., Van Deventer, H., Hainsworth, J., Leonard, J., Afanasayev, B., Chen, M., Seroogy, J., Escandon, R., Wolff, A., Conlan, M.

Volltext

A Novel Monoclonal Antibody Dependent on Domain 5 of the Platelet-Derived Growth Factor Beta Receptor Inhibits Ligand Binding and Receptor Activation von Ramakrishnan, Vanitha, Escobedo, Maria-Amelia, Fretto, Larry J, Seroogy, Joseph J, Tomlinson, James E, Wolf, David L

Volltext

Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists von Mehrotra, Mukund M., Heath, Julie A., Smyth, Mark S., Pandey, Anjali, Rose, Jack W., Seroogy, Joseph M., Volkots, Deborah L., Nannizzi-Alaimo, Lisa, Park, Gary L., Lambing, Joseph L., Hollenbach, Stanley J., Scarborough, Robert M.

Volltext

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes von MEHROTRA, Mukund M, HEATH, Julie A, PANDEY, Anjali, SCARBOROUGH, Robert M, ROSE, Jack W, SMYTH, Mark S, SEROOGY, Joseph, VOLKOTS, Deborah L, RUHTER, Gerd, SCHOTTEN, Theo, ALAIMO, Lisa, PARK, Gary

Volltext

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes von Pandey, A, Seroogy, J, Volkots, D, Smyth, M S, Rose, J, Mehrotra, M M, Heath, J, Ruhter, G, Schotten, T, Scarborough, R M

Volltext

SCIENCE SAFETY von Seroogy, J. Jack

Volltext